ReviewFrontiers in oncology2022
An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Fast intraoperative detection of primary central nervous system lymphoma and differentiation from common central nervous system tumors using stimulated Raman histology and deep learning.Neuro-oncology · 2025Article
- Surgical Considerations in Treating Central Nervous System Lymphomas: A Case Series of 11 Patients.Current oncology (Toronto, Ont.) · 2024Article
- Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS tumours.Journal of neuro-oncology · 2024Article
- Fast intraoperative detection of primary CNS lymphoma and differentiation from common CNS tumors using stimulated Raman histology and deep learning.medRxiv : the preprint server for health sciences · 2024Article
- Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.Acta neurochirurgica · 2024Review
- Primary Central Nervous System Lymphoma Mimicking the Presentation of Pituitary Apoplexy: A Case Report.Cureus · 2023Article
- Article
- [Imaging pathologies of the corpus callosum].Radiologie (Heidelberg, Germany) · 2023Article
- European survey on neurosurgical management of primary central nervous system lymphomas and preoperative corticosteroid therapy.Brain & spine · 2023Article
- [Imaging pathologies of the corpus callosum].Der Nervenarzt · 2022Article
- Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system lymphomas (PCNSL) are rare CNS tumors that harbor a conspicuously longer diagnostic delay compared to other malignant brain tumors. The gold standard for diagnosis is stereotactic biopsy to acquire tissue for histopathological analysis and therefore neurosurgery plays a central role when reducing the diagnostic period is mandated. However, histopathological diagnosis could be complicated if the patient was preoperatively exposed to corticosteroids. Besides the histopathological result, diagnosis of a PCNSL also requires full diagnostic workup to exclude cerebral metastatic disease of a systemic lymphoma. Most reviews of PCNSL discuss recent advancements in systemic treatment options from an (neuro-)oncologic viewpoint, whereas our intention was to discuss the optimization of the diagnostic period and therefore describe current standards of imaging, summarizing the diagnostic workup, discussing the surgical workup and future diagnostic prospects as well as the influence of preoperative corticosteroid therapy to reduce the diagnostic delay of PCNSL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.